Abstract
Since their discovery in the late 1980s, Hepatocyte growth factor (HGF) and its receptor, c-MET, have become the focus of intense scrutiny as regards their role in cancer and metastasis [1, 2]. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell growth and death and is a powerful angiogenic and lymphangiogenic factor [3-5]. The diverse range of functions that can be ascribed to HGF/c-MET is transmitted via a variety of cell signaling pathways. This review will focus on recent work demonstrating the importance of HGF/c-MET in regulating these signaling events, how they are related to cancer metastasis and where they may be targeted for patient intervention.
Keywords: Cancer, HGF, Metastasis, Signaling, c-MET, intracellular signalling, Grb2/SOS, Gab1, PI3 kinase, Stat3, Wnt signaling, Rho/Rac, Protein Kinase C, protein tyrosine phosphates, MAPK, mTOR, ERK, Mcl-1, RAS, MEK, LKB1, Cdc42, Mig6, Phospholipase C g-, cRaf, Catenin, Paxillin, FAK
Current Signal Transduction Therapy
Title: Hepatocyte Growth Factor Signaling in Cancer Metastasis
Volume: 6 Issue: 2
Author(s): Tracey A. Martin, Malcolm D. Mason and Wen G. Jiang
Affiliation:
Keywords: Cancer, HGF, Metastasis, Signaling, c-MET, intracellular signalling, Grb2/SOS, Gab1, PI3 kinase, Stat3, Wnt signaling, Rho/Rac, Protein Kinase C, protein tyrosine phosphates, MAPK, mTOR, ERK, Mcl-1, RAS, MEK, LKB1, Cdc42, Mig6, Phospholipase C g-, cRaf, Catenin, Paxillin, FAK
Abstract: Since their discovery in the late 1980s, Hepatocyte growth factor (HGF) and its receptor, c-MET, have become the focus of intense scrutiny as regards their role in cancer and metastasis [1, 2]. HGF is now known to be a potent morphogen that can regulate tissue and organ regeneration and modulate cell morphology, it is a motogen that can stimulate cell motility and migration, and is a mitogen able to regulate cell growth and death and is a powerful angiogenic and lymphangiogenic factor [3-5]. The diverse range of functions that can be ascribed to HGF/c-MET is transmitted via a variety of cell signaling pathways. This review will focus on recent work demonstrating the importance of HGF/c-MET in regulating these signaling events, how they are related to cancer metastasis and where they may be targeted for patient intervention.
Export Options
About this article
Cite this article as:
A. Martin Tracey, D. Mason Malcolm and G. Jiang Wen, Hepatocyte Growth Factor Signaling in Cancer Metastasis, Current Signal Transduction Therapy 2011; 6 (2) . https://dx.doi.org/10.2174/157436211795659991
DOI https://dx.doi.org/10.2174/157436211795659991 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurokinin-1 Receptor Antagonists in Lung Cancer Therapy
Letters in Drug Design & Discovery Meet Our Editorial Board Member:
Current Drug Targets Functions of Polo-Like Kinases: A Journey From Yeast To Humans
Protein & Peptide Letters The Anti-cancer Actions of Vitamin D
Anti-Cancer Agents in Medicinal Chemistry Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Current Medicinal Chemistry Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Sphingosine Kinases Signalling in Carcinogenesis
Mini-Reviews in Medicinal Chemistry Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs
Current Pharmaceutical Design Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Biotransformation of Endocrine Disrupting Compounds by Selected Phase I and Phase II Enzymes – Formation of Estrogenic and Chemically Reactive Metabolites by Cytochromes P450 and Sulfotransferases
Current Medicinal Chemistry Angiomodulatory and Neurological Effects of Ginsenosides
Current Medicinal Chemistry Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Novel Agents, Combinations and Sequences for the Treatment of Advanced Renal Cell Carcinoma: When is the Revolution Coming?
Current Cancer Drug Targets The Role of Maternal Serum Biomarkers in the Early Diagnosis of Ectopic Pregnancy
Current Chemical Biology Decoding the Knots of Initiation of Oncogenic Epithelial-Mesenchymal Transition in Tumor Progression
Current Cancer Drug Targets Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism Review of Estrone Sulfatase and its Inhibitors - An Important New Target Against Hormone Dependent Breast Cancer
Current Medicinal Chemistry An Updated Organic Classification of Tyrosinase Inhibitors on Melanin Biosynthesis
Current Organic Chemistry